Tg(CRBN)343Plbe
Transgene Detail
|
|
| Symbol: |
Tg(CRBN)343Plbe |
| Name: |
transgene insertion 343, P Leif Bergsagel |
| MGI ID: |
MGI:7429136 |
| Synonyms: |
hC343 |
| Transgene: |
Tg(CRBN)343Plbe Location: unknown Genetic Position: Chr1, Syntenic
|
| Alliance: |
Tg(CRBN)343Plbe page
|
|
| Strain of Origin: |
C57BL/6J
|
| Project Collection: |
APF ENU Mutagenesis
|
|
| Transgene Type: |
|
Transgenic (Inserted expressed sequence) |
| Mutation: |
|
Insertion
|
| |
|
Tg(CRBN)343Plbe expresses
1 gene
Transgene expresses:
| Organism |
Expressed Gene |
Homolog in Mouse |
Note |
| human |
CRBN (51185) |
|
|
|
| |
|
Mutation details: The transgene contains human BAC CTD-2197P5 (165kb hg38 chr3: chr3:3061496-3226738) containing CRBN, TRNT1 and IL5RA. Line 343 was generated.
(J:308274)
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
|
| Original: |
J:308274 Meermeier EW, et al., Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2(4):354-369 |
| All: |
2 reference(s) |
|
Analysis Tools
